Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,604 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Divi's Laboratories reported Q3 FY26 PAT of ₹583 crore, broadly flat YoY, impacted by a one-time exceptional charge of ₹74 crore due to labor code changes. Revenue mix improved with custom synthesis at 57% (9M), driving gross margin expansion as material consumption fell to 36.3% of sales (vs 39.8% YoY). Management highlighted strong volume traction in generics despite pricing pressure, and multiple CS projects progressing toward commercialization over the next year, with three dedicated facilities expected to start commercial volumes by Q3-Q4 CY2027. The peptide segment continues to advance, with a dedicated commercial building for large-scale SPS reactors now in validation. Backward integration at Unit 3 is supporting margins and freeing up GMP capacity. Key risk: pricing pressure in generics may persist longer than expected, limiting value growth.
Colored figures show movement against the previous available record.
Guidance to track
- Three custom synthesis dedicated facilities are expected to start commercial volumes in the second half of calendar 2027, pending customer regulatory approvals.
- Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline of late-lifecycle and new product launches.
- Excluding the three dedicated CS projects, capex is expected to be approximately in line with historical levels, with Phase 2 expansion at Unit 3 under evaluation.
Risks flagged
- Pricing environment in generics remains competitive, limiting value growth despite volume increases. Management noted no easing of pricing pressure.
- China's removal of export tax rebates on certain chemicals may increase raw material costs, though management has diversified 78% of procurement domestically.
- Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could slip beyond the targeted Q3-Q4 CY2027 timeline.
- While management claims a diversified basket, the three dedicated projects represent significant investment; any single project delay could impact near-term revenue visibility.
Key quotes
- As our managing director would say, the sky is the limit for you to dream.
- We have increased the use of process automation and multiple new chemistry platforms, scaling them into commercial manufacturing to improve process safety, minimize heat buildup for a more sustainable process.
- We are not hedging; we are evaluating at this point based on the overall scenario in the market.
Research modules